NASDAQ:URGN | Free Cash Flow | UroGen Pharma Ltd.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2015-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$45.32M$54,000.00-$45.37M
2025-12-31-$38.33M$17,000.00-$38.34M
2025-03-31-$42.02M$44,000.00-$42.07M
2024-12-31-$13.62M$115,000.00-$13.73M
2024-03-31-$31.74M$0.00-$31.74M
2023-12-31-$13M$56,000.00-$13.05M
2023-03-31-$25.81M$23,000.00-$25.83M
2022-12-31-$21.75M$13,000.00-$21.77M
2022-03-31-$24M$25,000.00-$24.02M
2021-12-31-$20.07M$202,000.00-$20.27M
2021-03-31-$27.4M$287,000.00-$27.69M
2020-12-31-$21.24M$172,000.00-$21.41M
2020-03-31-$35.64M$96,000.00-$35.73M
2019-12-31-$26M$192,000.00-$26.19M
2019-03-31-$17.93M$44,000.00-$17.98M
2018-12-31-$10.28M$24,000.00-$10.31M
2018-03-31-$9.62M$72,000.00-$9.7M
2017-12-31-$5.96M$153,000.00-$6.11M
2017-03-31-$2.75M$78,000.00-$2.82M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$162.44M$289,000.00-$162.73M
2024-12-31-$96.77M$295,000.00-$97.06M
2023-12-31-$76.38M$194,000.00-$76.57M
2022-12-31-$87.56M$254,000.00-$87.81M
2021-12-31-$84.89M$752,000.00-$85.64M
2020-12-31-$105.89M$1.22M-$107.1M
2019-12-31-$71.02M$325,000.00-$71.34M
2018-12-31-$37.33M$560,000.00-$37.89M
2017-12-31-$9.57M$271,000.00-$9.84M
2016-12-31$4.19M$695,000.00$3.49M
2015-12-31-$7.18M$301,000.00-$7.48M

Research interface only. Not investment advice. Prices are a checked-in snapshot, not live quotes.